Stockscreener 앱 받기
1.44
0.69%
-0.01
전일 마감가:
$1.45
열려 있는:
$1.46
하루 거래량:
402.41K
Relative Volume:
0.49
시가총액:
$163.50M
수익:
$27.08M
순이익/손실:
$-37.00M
주가수익비율:
-2.7692
EPS:
-0.52
순현금흐름:
$-18.46M
1주 성능:
-7.69%
1개월 성능:
-2.04%
6개월 성능:
-44.62%
1년 성능:
+25.22%
1일 변동 폭
$1.44
$1.4899
1주일 범위
$1.3801
$1.63
52주 변동 폭
$1.05
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
명칭
Aclaris Therapeutics Inc
전화
484-324-7933
주소
701 LEE ROAD, WAYNE, PA
ACRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
1.44 | 163.50M | 27.08M | -37.00M | -18.46M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-28 | 개시 | Wedbush | Outperform |
| 2025-03-18 | 재개 | Cantor Fitzgerald | Overweight |
| 2024-12-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-11-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-19 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | 개시 | Evercore ISI | Outperform |
| 2022-12-14 | 개시 | Stifel | Buy |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2022-10-06 | 개시 | BTIG Research | Buy |
| 2021-07-23 | 재개 | Jefferies | Buy |
| 2021-06-15 | 개시 | Piper Sandler | Overweight |
| 2021-04-21 | 개시 | H.C. Wainwright | Buy |
| 2019-10-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | 개시 | SVB Leerink | Outperform |
| 2018-03-28 | 재개 | Leerink Partners | Outperform |
| 2018-02-09 | 개시 | Guggenheim | Buy |
| 2017-06-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-29 | 개시 | Leerink Partners | Outperform |
| 2016-09-30 | 개시 | JMP Securities | Mkt Outperform |
| 2016-06-10 | 개시 | Guggenheim | Buy |
| 2015-11-02 | 개시 | Citigroup | Buy |
| 2015-11-02 | 개시 | Jefferies | Buy |
모두보기
Aclaris Therapeutics Inc 주식(ACRS)의 최신 뉴스
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $9.71 Consensus Price Target from Analysts - Defense World
Revenues Not Telling The Story For Aclaris Therapeutics, Inc. (NASDAQ:ACRS) After Shares Rise 26% - simplywall.st
Aclaris at Goldman Sachs Conference: Strategic Focus on Immuno-inflammatory Pipeline By Investing.com - Investing.com South Africa
Aclaris at Goldman Sachs Conference: Strategic Focus on Immuno-inflammatory Pipeline - Investing.com Australia
Bank of America Corp DE Buys 196,708 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Vitiligo Drugs Market Exclusive Report with Detailed Study Analysis | Dermavant Sciences, Aclaris Therapeutics - newstrail.com
H.C. Wainwright maintains Buy on Aclaris stock, $16 target By Investing.com - Investing.com Canada
Aclaris Therapeutics Approves 2025 Equity Incentive Plan - TipRanks
Aclaris Therapeutics at Jefferies Conference: Strategic Pipeline Advances By Investing.com - Investing.com Canada
Aclaris Therapeutics to Present at Two Major Healthcare Conferences in June 2025 - MSN
Transcript : Aclaris Therapeutics, Inc. Presents at H.C. Wainwright ?HCW@Home? series, May-16-2025 01 - marketscreener.com
Aclaris begins phase 2 trial for atopic dermatitis drug By Investing.com - Investing.com South Africa
Aclaris Therapeutics, Inc. Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - marketscreener.com
Aclaris begins phase 2 trial for atopic dermatitis drug - Investing.com Australia
Aclaris Therapeutics (ACRS) Begins Phase 2 Trial for Atopic Dermatitis Treatment | ACRS Stock News - GuruFocus
Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - GlobeNewswire
Two Sigma Investments LP Sells 68,646 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Northern Trust Corp Has $434,000 Stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates - MSN
What is Wedbush’s Forecast for ACRS Q2 Earnings? - Defense World
Millennium Management LLC Decreases Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Aclaris Therapeutics (NASDAQ:ACRS) Coverage Initiated by Analysts at Wedbush - Defense World
Aclaris Therapeutics to Participate in Two June Healthcare Conferences - GlobeNewswire
Aclaris Therapeutics Secures Double Speaking Slots at Major June Healthcare Conferences - Stock Titan
Wedbush sets Aclaris stock Outperform with $8 target By Investing.com - Investing.com India
Wedbush Initiates Coverage of Aclaris Therapeutics (ACRS) with Outperform Recommendation - Nasdaq
Aclaris Therapeutics (ACRS) Receives Outperform Rating from Wedbush | ACRS Stock News - GuruFocus
This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Aclaris Therapeutics (ACRS) Receives Positive Outlook from Wedbush | ACRS Stock News - GuruFocus
Aclaris Therapeutics (ACRS) Receives Positive Rating from Wedbus - GuruFocus
Wedbush Initiates Aclaris Therapeutics at Outperform With $8 Price Target - marketscreener.com
Costco (COST) Is About to Report Q3 Earnings. Here’s What to Expect - The Globe and Mail
Aclaris Therapeutics (ACRS) Receives Positive Outlook from Wedbu - GuruFocus
Options Volatility and Implied Earnings Moves Today, May 27, 2025 - The Globe and Mail
Prediction: This Will Be the First Mega Technology Company to Split Its Stock in 2025 (and It Isn't Tesla) - The Globe and Mail
Common Warts Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Verrica Pharma, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics, KinoPharma Inc - The Globe and Mail
Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) PT at $10.00 - Defense World
vTv Therapeutics Advances First-in-Class Oral Type 1 Diabetes Drug as New CFO Joins - Stock Titan
HC Wainwright Has Positive Forecast for ACRS Q3 Earnings - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Holdings Raised by Dimensional Fund Advisors LP - Defense World
Aclaris Therapeutics to Host Virtual Fireside Chat with CEO Neal Walker on May 16, 2025 - MSN
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stake Reduced by Price T Rowe Associates Inc. MD - Defense World
Aclaris Therapeutics (ACRS) Price Target Update by HC Wainwright & Co. | ACRS Stock News - GuruFocus
Aclaris Therapeutics (ACRS) Receives Lower Price Target from Ana - GuruFocus
Aclaris Therapeutics Reports Q1 2025 Financial Results - MSN
Androgenetic alopecia Pipeline 2025: Groundbreaking Clinical - openPR.com
Aclaris Therapeutics Reports Q1 2025 Results and Pipeline Updates - MSN
Aclaris Therapeutics Welcomes Dr. Jesse Hall as Chief Medical Officer - MSN
Scotiabank Has Lowered Expectations for Aclaris Therapeutics (NASDAQ:ACRS) Stock Price - Defense World
Aclaris Therapeutics (ACRS) Price Target Lowered by Scotiabank | - GuruFocus
Aclaris Therapeutics First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo
Aclaris Therapeutics Inc (ACRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Aclaris Therapeutics Inc 주식 (ACRS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Mehra Anand | Director |
Nov 19 '24 |
Buy |
2.25 |
666,666 |
1,499,998 |
710,030 |
| Walker Neal | INTERIM PRESIDENT AND CEO |
Aug 09 '24 |
Option Exercise |
0.72 |
43,548 |
31,355 |
1,356,153 |
| Leonard Braden Michael | 10% Owner |
Aug 05 '24 |
Buy |
1.24 |
206,025 |
256,357 |
14,250,000 |
| Leonard Braden Michael | 10% Owner |
Aug 02 '24 |
Buy |
1.29 |
167,544 |
216,400 |
14,043,975 |
| Leonard Braden Michael | 10% Owner |
Jul 30 '24 |
Buy |
1.30 |
173,730 |
226,370 |
13,776,421 |
| Leonard Braden Michael | 10% Owner |
Jul 31 '24 |
Buy |
1.33 |
100,000 |
132,640 |
13,876,421 |
| Leonard Braden Michael | 10% Owner |
Jul 18 '24 |
Buy |
1.30 |
130,317 |
169,555 |
13,578,286 |
| Leonard Braden Michael | 10% Owner |
Jul 22 '24 |
Buy |
1.33 |
17,716 |
23,557 |
13,602,691 |
| Leonard Braden Michael | 10% Owner |
Jul 19 '24 |
Buy |
1.30 |
6,689 |
8,696 |
13,584,975 |
0.68%
0.50%
자본화:
|
볼륨(24시간):